1035 related articles for article (PubMed ID: 9808873)
21. Clinical impact of local implementation of agreed guidelines for the management of patients with acute myocardial infarction.
Badano L; Cassin M; Solinas L; Burelli C; Macor F; Zanuttini D
G Ital Cardiol; 1999 Jan; 29(1):39-47. PubMed ID: 9987046
[TBL] [Abstract][Full Text] [Related]
22. Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction.
Bassand JP; Cariou R; Grollier G; Kragten J; Wolf JE; Heyndrickx GR
Semin Thromb Hemost; 1999; 25 Suppl 2():69-75. PubMed ID: 10440428
[TBL] [Abstract][Full Text] [Related]
23. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
[TBL] [Abstract][Full Text] [Related]
24. Thrombolysis utilisation in acute myocardial infarction in Bahrain.
Chawla AK; Nambiar CA; Murad AA
Indian Heart J; 1996; 48(2):155-8. PubMed ID: 8682556
[TBL] [Abstract][Full Text] [Related]
25. Effects of thrombolytic therapy on recanalization in different starting time of treatment after acute myocardial infarction.
Shen L; Yang J; Hu Q; Teng Y; Han X; Yan S; Lian M; Xie M; Gu F
Chin Med J (Engl); 1997 Jan; 110(1):53-5. PubMed ID: 9594323
[TBL] [Abstract][Full Text] [Related]
26. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
Cugno M; Cicardi M; Colucci M; Bisiani G; Merlini PA; Spinola A; Paonessa R; Agostoni A
Thromb Haemost; 1996 Aug; 76(2):234-8. PubMed ID: 8865537
[TBL] [Abstract][Full Text] [Related]
27. Megadose heparin and streptokinase produce similar TIMI 3 flow at discharge in patients of acute myocardial infarction presenting between 7-12 hours.
Dwivedi SK; Pramod K; Gupta R; Saran RK; Narain VS; Puri VK
Indian Heart J; 2000; 52(2):183-6. PubMed ID: 10893895
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of recombinant tissue-type plasminogen activator thrombolysis and primary coronary stenting after acute myocardial infarction.
Chen B; Wang W; Zhao H; Hu D; Xu C; Zhao M; Lu M; Liu J; Wu C
Chin Med J (Engl); 2003 Jan; 116(1):142-4. PubMed ID: 12667408
[TBL] [Abstract][Full Text] [Related]
29. [Repeat thrombolysis in acute myocardial infarction].
Király C; Timár S
Orv Hetil; 2001 Apr; 142(13):665-9. PubMed ID: 11338569
[TBL] [Abstract][Full Text] [Related]
30. [Myocardial infarction treated within 4 hrs: comparison of the cost-benefit ratio of 3 thrombolytic treatments: APSAC, rt-PA and streptokinase in 270 patients].
Machecourt J; Cassagnes J; Bassand JP; Dumoulin J; Calop J; Foroni L; Terrisse MP; Hénon T; Petit L; Denis B
Arch Mal Coeur Vaiss; 1993 Feb; 86(2):209-17. PubMed ID: 8363422
[TBL] [Abstract][Full Text] [Related]
31. Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction.
Wagner A; Herkner H; Schreiber W; Bur A; Woisetschläger C; Stix G; Laggner AN; Hirschl MM
Thromb Haemost; 2002 Aug; 88(2):180-5. PubMed ID: 12195686
[TBL] [Abstract][Full Text] [Related]
32. [Impact of intravenous thrombolysis prior to percutaneous coronary intervention in reperfusion therapy for acute myocardial infarction].
Uto K; Ota Y; Mizuno M; Nakamura A; Nakajima R; Endoh Y; Kasanuki H
J Cardiol; 2002 Dec; 40(6):241-8. PubMed ID: 12528645
[TBL] [Abstract][Full Text] [Related]
33. [Thrombolytic therapy in acute myocardial infarct--is it being used to the fullest?].
Carôla B; Calçada-Correia L; Pedro PG; Conduto R; Dionísio I; Fiuza M; Dias E; Vaz Carneiro A; Amador MG; de Pádua F; Lopes MG
Rev Port Cardiol; 1996 Dec; 15(12):867-76, 863. PubMed ID: 9052962
[TBL] [Abstract][Full Text] [Related]
34. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
[TBL] [Abstract][Full Text] [Related]
35. [Thrombolytic therapy for acute myocardial infarction: circadian sensitivity].
Kharash LM; Goldkhammer EI
Ter Arkh; 1999; 71(12):13-7. PubMed ID: 10647192
[TBL] [Abstract][Full Text] [Related]
36. Clinical trial of China-made recombinant streptokinase in acute myocardial infarction. Collaborative Study Group on Thrombolysis with China-made recombinant streptokinase.
Chin Med J (Engl); 1997 Jan; 110(1):50-2. PubMed ID: 9594322
[TBL] [Abstract][Full Text] [Related]
37. [Thrombolysis in acute myocardial infarction. Streptokinase or r-TPA?].
Silva LA; Ribeiro E; Carneiro RC; Kaissar S; Reis Filho A; Torossian SP; Tavares JR; Buffolo E; Amino JG; Duprat Filho R
Arq Bras Cardiol; 1990 Jul; 55(1):13-7. PubMed ID: 2127353
[TBL] [Abstract][Full Text] [Related]
38. Influence of cardiac output on peak t-PA plasma levels in patients receiving thrombolytic therapy with recombinant tissue-type plasminogen activator--correlation with patency rate.
Huber K; Beckmann R; Probst P; Rauscha F; Kaindl F; Binder BR
Thromb Haemost; 1993 Jan; 69(1):45-9. PubMed ID: 8446938
[TBL] [Abstract][Full Text] [Related]
39. Beneficial effects of diltiazem during myocardial reperfusion: a randomized trial in acute myocardial infarction.
Pizzetti G; Mailhac A; Li Volsi L; Di Marco F; Lu C; Margonato A; Chierchia SL
Ital Heart J; 2001 Oct; 2(10):757-65. PubMed ID: 11721720
[TBL] [Abstract][Full Text] [Related]
40. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.
Steg PG; Bonnefoy E; Chabaud S; Lapostolle F; Dubien PY; Cristofini P; Leizorovicz A; Touboul P;
Circulation; 2003 Dec; 108(23):2851-6. PubMed ID: 14623806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
